Agios Pharmaceuticals: Biotech Company With Upcoming FDA Approvals and Promising Pipeline
Agios Pharmaceuticals is developing therapies for rare diseases with a focus on pyruvate kinase activators such as Pyrukynd for PK deficiency. AGIO is advancing its pipeline with mitapivate research for thalassemia and sickle cell anemia and is positioning for potential FDA approvals in 2025 and 2026. Potential FDA approvals could significantly increase AGIO's revenues. Agios Pharmaceuticals (NASDAQ: AGIO) is a biotechnology company at the forefront of developing therapies for rare diseases. The company's flagship drug, Pyrukynd (mitapivate),...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
Already registered? Log In
At an event, Tesla CEO Elon Musk explained his thoughts on the future of the electric car manufacturer and the influence of AI. Investors and Teslafans...
At Adobe MAX, the world's largest creative trade show, held from October 10 to October 12, the leading image-editing software provider unveiled new models...
array (
'ID' => '4632',
'post_author' =>
array (
'ID' => '3',
'user_url' => '',
'display_name' => 'Chiara Ferrario',
'user_registered' => '2023-09-12 13:13:33',
'nickname' => 'ChiaraFerrario',
'first_name' => 'Chiara',
'last_name' => 'Ferrario',
'description' => '',
'description_en' => '',
'description_es' => '',
'description_fr' => '',
'description_it' => '',
'freelancer' => '0',
'passive' => '0',
'twitter_link' => '',
'profile_image' => '',
'name' => 'Chiara Ferrario',
'name_short' => 'C. Ferrario',
'slug' => 'chiara-ferrario',
),
'post_date' => '2024-07-29 11:46:46',
'post_date_gmt' => '2024-07-29 09:46:46',
'post_content' => '
- Agios Pharmaceuticals is developing therapies for rare diseases with a focus on pyruvate kinase activators such as Pyrukynd for PK deficiency.
- AGIO is advancing its pipeline with mitapivate research for thalassemia and sickle cell anemia and is positioning for potential FDA approvals in 2025 and 2026.
- Potential FDA approvals could significantly increase AGIO\'s revenues.
Agios Pharmaceuticals (NASDAQ: AGIO) is a biotechnology company at the forefront of developing therapies for rare diseases. The company\'s flagship drug, Pyrukynd (mitapivate), an activator of pyruvate kinase [PK], is approved in the US, EU and UK for the treatment of PK deficiency in adults. In addition, AGIO is advancing its pipeline and exploring additional indications for mitapivat, including other subtypes of thalassemia. AGIO is also developing a treatment for sickle cell disease and other drug candidates to address unmet medical needs in rare diseases. In May 2025, AGIO announced an agreement with Royalty Pharma when it sold 15% of its royalty interest in vorasidenib, resulting in an upfront payment of $905 million contingent on FDA approval.
Rare diseases: Business overview
Agios Pharmaceuticals develops therapies for rare diseases and is a leader in research to control cell metabolism, which converts nutrients into energy to sustain cell life. AGIO currently has a commercial drug called Pyrukynd, or mitapivate, a pyruvate kinase [PK] activator approved in the US, EU and UK for the treatment of PK deficiency in adults. The mechanism of action of AGIO\'s Pyrukynd focuses on PK, an enzyme that interferes with the cellular process of converting glucose into energy. The PK activator enhances the enzyme\'s activity to treat rare diseases such as pyruvate kinase deficiency, which is characterized by the destruction of red blood cells and leads to anemia, debilitating fatigue and memory loss, among other symptoms. AGIO\'s PK activators stabilize red blood cells and reduce the signs of the disease. In addition, AGIO\'s pipeline includes other potential indications for mitapivate and other drug candidates currently in various stages of clinical development.
Royalty Pharma and Servier agreements
On May 28, AGIO announced an agreement with Royalty Pharma for the sale of 15 % of the royalties for vorasidenib, a brain tumor drug. AGIO also sold its oncology portfolio, including vorasidenib, to the French company Servier in 2021. AGIO retained the rights to $200 million upon achieving FDA approval and 15% royalties on US net sales. The agreement was signed after the FDA and EMA accepted the marketing application for vorasidenib and granted priority review for a new drug application for the treatment of IDH-mutated diffuse glioma with a PDUFA date of August 20, 2024. This means that AGIO will receive $905 million upfront from RPRX, subject to FDA approval of vorasidenib. This agreement with RPRX will provide AGIO with potentially significant funding, strengthen the company\'s financial position and support ongoing efforts to advance the pipeline, particularly Pyrukynd.
Summary: AGIO\'s Q1 2024 earnings presentation noted that thalassemia indications for Pyrukynd are expected to receive FDA approval by 2025. All subtypes, transfusion-dependent and non-transfusion-dependent forms of this disease affect more than 1 million patients worldwide. The company is not yet profitable, so caution is advised.
',
'post_title' => 'Agios Pharmaceuticals: Biotech Company With Upcoming FDA Approvals and Promising Pipeline',
'post_excerpt' => '',
'post_status' => 'publish',
'comment_status' => 'open',
'ping_status' => 'open',
'post_password' => '',
'post_name' => 'agios-pharmaceuticals-biotech-company-with-upcoming-fda-approvals-and-promising-pipeline',
'to_ping' => '',
'pinged' => '',
'post_modified' => '2024-07-29 11:46:46',
'post_modified_gmt' => '2024-07-29 09:46:46',
'post_content_filtered' => '',
'post_parent' => '0',
'guid' => 'https://tradertimes.com/wordpress/?p=4632',
'menu_order' => '0',
'post_type' => 'post',
'post_mime_type' => '',
'comment_count' => '0',
'_encloseme' => '1',
'_pingme' => '1',
'magazine' =>
array (
'ID' => '4636',
'post_title' => 'The Trader Times #141 dated July 29, 2024',
'post_content' => '',
'post_date' => '2024-07-29 11:45:27',
'post_type' => 'tradertimes',
'post_mime_type' => '',
'post_parent' => '0',
),
'seo_description' => '',
'seo_image' => '',
'seo_title' => '',
'teaser' => '',
'category' =>
array (
9 =>
array (
'term_id' => '9',
'term_taxonomy_id' => '9',
'name' => 'Top Stories',
'slug' => 'top-stories',
'description' => '',
'parent' => '0',
'lang_term_taxonomy_id' => '8',
'lang_term_id' => '8',
'lang_name' => 'English',
'lang_slug' => 'en',
'translations' =>
array (
'de' => 1,
'en' => 9,
'es' => 13,
'fr' => 17,
'it' => 21,
),
'seo_title' => '',
'seo_description' => '',
'seo_image' => '',
'sub_ids' =>
array (
0 => 9,
),
'link' => '/top-stories/',
),
),
'link' => '/top-stories/agios-pharmaceuticals-biotech-company-with-upcoming-fda-approvals-and-promising-pipeline-4632.html',
'image' =>
array (
'ID' => '4631',
'post_title' => 'Unbenannt-1',
'post_content' => '',
'post_date' => '2024-07-29 10:19:28',
'post_type' => 'attachment',
'post_mime_type' => 'image/png',
'post_parent' => '4629',
'src' => 'https://tradertimes.com/files/2024/07/Unbenannt-1.png',
'width' => 1200,
'height' => 628,
'sizes' =>
array (
'thumbnail' =>
array (
'file' => 'https://tradertimes.com/files/2024/07/Unbenannt-1-150x150.png',
'width' => 150,
'height' => 150,
'mime-type' => 'image/png',
'filesize' => 35553,
),
'teaser' =>
array (
'file' => 'https://tradertimes.com/files/2024/07/Unbenannt-1-632x280.png',
'width' => 632,
'height' => 280,
'mime-type' => 'image/png',
'filesize' => 202842,
),
'fb' =>
array (
'file' => 'https://tradertimes.com/files/2024/07/Unbenannt-1-1200x628.png',
'width' => 1200,
'height' => 628,
'mime-type' => 'image/png',
'cpt_last_cropping_data' =>
array (
'x' => 0,
'y' => 0,
'x2' => 1199,
'y2' => 628,
'original_width' => 1200,
'original_height' => 628,
),
),
),
),
'translations' =>
array (
'de' =>
array (
'post_title' => 'Agios Pharmaceuticals: Biotech-Unternehmen mit bevorstehender FDA-Zulassungen und vielversprechender Pipeline',
'post_name' => '',
'ID' => '4629',
'post_type' => 'post',
'link' => '/de/top-storys/-4629.html',
),
'en' =>
array (
'post_title' => 'Agios Pharmaceuticals: Biotech Company With Upcoming FDA Approvals and Promising Pipeline',
'post_name' => 'agios-pharmaceuticals-biotech-company-with-upcoming-fda-approvals-and-promising-pipeline',
'ID' => '4632',
'post_type' => 'post',
'link' => '/top-stories/agios-pharmaceuticals-biotech-company-with-upcoming-fda-approvals-and-promising-pipeline-4632.html',
),
'es' =>
array (
'post_title' => 'Agios Pharmaceuticals: empresa biotecnológica con próximas aprobaciones de la FDA y una prometedora cartera de productos en desarrollo',
'post_name' => 'agios-pharmaceuticals-empresa-biotecnolgica-con-prximas-aprobaciones-de-la-fda-y-una-prometedora-cartera-de-productos-en-desarrollo',
'ID' => '4633',
'post_type' => 'post',
'link' => '/es/noticias-principales/agios-pharmaceuticals-empresa-biotecnolgica-con-prximas-aprobaciones-de-la-fda-y-una-prometedora-cartera-de-productos-en-desarrollo-4633.html',
),
),
)
